reply by damian, page-8

Reiner,

As far as I know, IPs have limited lengths of lives, so the values of IPs should also decrease as the remaining paten life shortens. If Biota can not sell, advance or partner for its HCV IPs, then, what is the HCV IPs' value to Biota shareholders?

I am not an expert in this area. I may miss something. This is my opinion only.

Of course, it is good to hear that the company is confident of retaining this IP.